Valeant Pharmaceuticals Intern... : VRX

All VRX Articles

185 Articles

Paul Ausick | Mar 6, 2017 at 4:04 PM EST

Rite Aid, Frontier Communications Tumble into Monday’s 52-Week Low Club

Rite Aid, Valeant, Frontier Communications, and DryShips all posted new 52-week lows on Monday.

Chris Lange | Mar 6, 2017 at 3:45 PM EST

Why One Key Analyst Believes That Valeant Is Kicking the Can in Its Restructuring Deal

Valeant Pharmaceuticals announced that it intends to refinance some of its debt. One key analyst thinks that this might be…

Chris Lange | Mar 4, 2017 at 9:45 AM EST

Why Analysts Are Looking at Valeant Pharma Differently After Earnings

Valeant Pharmaceuticals shares hit a multiyear low this past week, and some analysts took this opportunity to reevaluate their stance…

Paul Ausick | Mar 3, 2017 at 4:04 PM EST

Target, Valeant Slide into Friday’s 52-Week Low Club

Target, Valeant, DryShips, and SeaDrill posted new 52-week lows on Friday.

Chris Lange | Feb 28, 2017 at 12:05 PM EST

Why Valeant Missed the Mark Despite an Earnings Beat

Valeant Pharmaceuticals reported better-than-expected fourth-quarter financial results before the markets opened on Tuesday.

Chris Lange | Feb 26, 2017 at 10:25 AM EST

6 Key Earnings to Look For This Week

24/7 Wall St. has put together a preview of Valeant Pharmaceuticals, Salesforce.com and some of the other major companies reporting…

Chris Lange | Feb 25, 2017 at 10:25 AM EST

Top Biopharma Movers of the Past Week

The health care sector was in trouble over the past year, under fire from congressional hearings and politicians on the…

Chris Lange | Feb 21, 2017 at 11:10 AM EST

Tuesday’s Top Biopharma Movers

A few biopharma companies have made massive runs on Tuesday morning.

Chris Lange | Feb 16, 2017 at 12:05 PM EST

Why This FDA Approval for Valeant Is Not as Good as First Thought

Valeant Pharmaceuticals received a key FDA approval early on Thursday, but it seems to be a mixed blessing.

Chris Lange | Jan 11, 2017 at 3:22 PM EST

Wednesday’s Top Biopharma Movers

Biotech and pharma companies were on the move Wednesday. A few of the smaller caps made tremendous gains on the…

Chris Lange | Jan 10, 2017 at 3:30 PM EST

Tuesday’s Top Biopharma Movers

Considering the new Trump administration, there is an increasingly positive sentiment in the health care sector. In the past year,…

Chris Lange | Jan 10, 2017 at 11:05 AM EST

Why Valeant Is Making a Run

Valeant Pharmaceuticals made waves early on Tuesday after the company offered announcements of a late-stage psoriasis trial and the sale…

Douglas A. McIntyre | Dec 18, 2016 at 9:46 AM EST

CEOs Who Were Fired or Forced Out in 2016: Macy’s, Wells Fargo, Valeant and More

Several high-profile CEOs lost their jobs in 2016, along with one or two who "resigned" with the cooperation of their…

Lee Jackson | Dec 17, 2016 at 9:45 AM EST

Massive Bill Ackman Trade Highlights Insider Selling: Valeant Pharmaceuticals, Starbucks, Schlumberger, Validus and More

While the selling was robust, it certainly wasn’t extraordinary, and it should be expected given the big run in the…

Paul Ausick | Dec 15, 2016 at 4:04 PM EST

Valeant, HiMax Lead Thursday’s 52-Week Low Club

December 15, 2016: Here are four stocks trading with relatively heavy volume among 65 equities making new 52-week lows in…

1 2 3 4 5 6 … 13

Valeant Pharmaceuticals Intern... : VRX

All VRX Articles

Rite Aid, Frontier Communications Tumble into Monday’s 52-Week Low Club

Why One Key Analyst Believes That Valeant Is Kicking the Can in Its Restructuring Deal

Why Analysts Are Looking at Valeant Pharma Differently After Earnings

Target, Valeant Slide into Friday’s 52-Week Low Club

Why Valeant Missed the Mark Despite an Earnings Beat

6 Key Earnings to Look For This Week

Top Biopharma Movers of the Past Week

Tuesday’s Top Biopharma Movers

Why This FDA Approval for Valeant Is Not as Good as First Thought

Wednesday’s Top Biopharma Movers

Tuesday’s Top Biopharma Movers

Why Valeant Is Making a Run

CEOs Who Were Fired or Forced Out in 2016: Macy’s, Wells Fargo, Valeant and More

Massive Bill Ackman Trade Highlights Insider Selling: Valeant Pharmaceuticals, Starbucks, Schlumberger, Validus and More

Valeant, HiMax Lead Thursday’s 52-Week Low Club

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

QDVO’s 32% Return Masks a Hidden Risk for Income Investors

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

QDVO’s 32% Return Masks a Hidden Risk for Income Investors

Valeant Pharmaceuticals Intern... : VRX

All VRX Articles

Rite Aid, Frontier Communications Tumble into Monday’s 52-Week Low Club

Why One Key Analyst Believes That Valeant Is Kicking the Can in Its Restructuring Deal

Why Analysts Are Looking at Valeant Pharma Differently After Earnings

Target, Valeant Slide into Friday’s 52-Week Low Club

Why Valeant Missed the Mark Despite an Earnings Beat

6 Key Earnings to Look For This Week

Top Biopharma Movers of the Past Week

Tuesday’s Top Biopharma Movers

Why This FDA Approval for Valeant Is Not as Good as First Thought

Wednesday’s Top Biopharma Movers

Tuesday’s Top Biopharma Movers

Why Valeant Is Making a Run

CEOs Who Were Fired or Forced Out in 2016: Macy’s, Wells Fargo, Valeant and More

Massive Bill Ackman Trade Highlights Insider Selling: Valeant Pharmaceuticals, Starbucks, Schlumberger, Validus and More

Valeant, HiMax Lead Thursday’s 52-Week Low Club

XRP Price Prediction: 3 AI Models Predict Where XRP Will Trade by December 2026

QDVO’s 32% Return Masks a Hidden Risk for Income Investors

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

Featured Reads

Half of America Still Feels Financially Exposed Despite 8% Jump in Security

52% of Americans Are Building Wealth While Ignoring Their Greatest Risk